Patent details

300507 Product Name: Telavancine, of een farmaceutisch aanvaardbaar zout daarvan, inclusief telavancine hydrocloride.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300507
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1292612
Status:
Invalid because the basic patent has lapsed before the expiration date or has been revoked
Application number:
300507
Procedural language:
Dutch
First Applicant Residence Country:

Marketing Authorization

Marketing Authorization Number:
EU/1/11/705/001 - 002
Marketing Authorization Type:
EEA
Marketing Authorization Date:
02/09/2011
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
05/12/2011
First Marketing Authorization date:
02/09/2011
Grant date:
12/01/2012
Activation date:
01/05/2021
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
05/12/2011
SPC/SPC Extension Expiration Date:
30/04/2026
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
10/11/2015
 
 

 

Name:
Theravance Biopharma Antibiotics IP, LLC.
Address:
901 Gateway Boulevard, 94080, South San Francisco, California, United States of America (US)

Historical Applicant/holder

From:
10/11/2015
To:
10/11/2015

 

Name:
Theravance, Inc.
Address:
951 Gateway Boulevard, 94080, South San Francisco, California, United States of America (US)

Agent

Name:
ir. J.C. Volmer c.s.
From:
05/12/2011
Address:
Exter Polak & Charlouis B.V. Postbus 3241, 2280 GE, Rijswijk, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
02/20
Publication date:
13/01/2020
Description:
Lapse or annulment

2

Bulletin Heading:
CO
Journal edition number:
12/16
Publication date:
23/03/2016
Description:
Changes in the Netherlands Patent Register

3

Bulletin Heading:
SPC
Journal edition number:
2012/04
Publication date:
25/01/2012
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

4

Bulletin Heading:
SPC
Journal edition number:
2011/50
Publication date:
14/12/2011
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Deed

Change of Address

Change Kind/ Decision Type:
Owner
Deed Number:
RC201600362A
Date Registered:
10/11/2015
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. J.C. Volmer c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC201600362B
Date Registered:
10/11/2015
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. J.C. Volmer c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
Theravance Biopharma Antibiotics IP, LLC.
Address:
901 Gateway Boulevard, 94080, South San Francisco, California, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
30/04/2021
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type
12/01/2012 SPC Documents Certificate SPC 1 PDF /7/0/5/0/0/0400300507/docs/300507_4_supplprotectioncertificate20200909050409832.pdf
12/01/2012 Outgoing Correspondence Outgoing Letter 2 PDF /7/0/5/0/0/0400300507/docs/300507_9_outgoingcorrespondence20120112.pdf
17/12/2011 Application Form First filed application form 2 PDF /7/0/5/0/0/0400300507/docs/300507_7_applicationform20111205.pdf
06/12/2011 Outgoing Correspondence Outgoing Letter 1 PDF /7/0/5/0/0/0400300507/docs/300507_8_outgoingcorrespondence20111206.pdf
05/12/2011 SPC Documents Annex SPC 3 PDF /7/0/5/0/0/0400300507/docs/300507_0_supplprotectioncertificate20200909051229641.pdf
05/12/2011 SPC Documents Marketing Authorization SPC 4 PDF /7/0/5/0/0/0400300507/docs/300507_1_supplprotectioncertificate20200909050002670.pdf
05/12/2011 SPC Documents Annex SPC 3 PDF /7/0/5/0/0/0400300507/docs/300507_2_supplprotectioncertificate20200909045556785.pdf
05/12/2011 SPC Documents Annex SPC 17 PDF /7/0/5/0/0/0400300507/docs/300507_3_supplprotectioncertificate20200909045556683.pdf
05/12/2011 SPC Documents Accompanying letter SPC 1 PDF /7/0/5/0/0/0400300507/docs/300507_5_supplprotectioncertificate20200909050145400.pdf
05/12/2011 SPC Documents Summary of the characteristics of the product 27 PDF /7/0/5/0/0/0400300507/docs/300507_6_supplprotectioncertificate20200909045556611.pdf